These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15869020)

  • 21. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long term--maximising potential for rehabilitation in patients with schizophrenia.
    Fagiolini A; Goracci A
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S123-9. PubMed ID: 17336767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotic therapy and hyperlipidemia: a review.
    Koro CE; Meyer JM
    Essent Psychopharmacol; 2005; 6(3):148-57. PubMed ID: 15869022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
    Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
    Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Polypharmacy in the treatment of schizophrenia].
    Messer T; Tiltscher C; Schmauss M
    Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical perspectives on atypical antipsychotics for treatment of agitation.
    Caine ED
    J Clin Psychiatry; 2006; 67 Suppl 10():22-31. PubMed ID: 16965192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychiatric medication-induced obesity: treatment options.
    Schwartz TL; Nihalani N; Virk S; Jindal S; Chilton M
    Obes Rev; 2004 Nov; 5(4):233-8. PubMed ID: 15458397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A new study of secondary effects in prescribing practices of neuroleptics].
    Lachaux B; Sechter D; Morasz L; Adouard D
    Encephale; 1997 Apr; 23 Spec No 2():25-34. PubMed ID: 9273304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polypharmacy in schizophrenia.
    Baandrup L
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):183-192. PubMed ID: 31908124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychiatric medication induced obesity: an aetiologic review.
    Virk S; Schwartz TL; Jindal S; Nihalani N; Jones N
    Obes Rev; 2004 Aug; 5(3):167-70. PubMed ID: 15245385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.